Mutant LRRK2 enhances glutamatergic synapse activity and evokes excitotoxic dendrite degeneration

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1842, Issue 9, 2014, Pages 1596-1603

  Plowey, Edward D ^a,d   Johnson, Jon W ^a,b   Steer, Erin ^a   Zhu, Wan ^d   Eisenberg, David A ^a   Valentino, Natalie M ^a   Liu, Yong Jian ^c   Chu, Charleen T ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c NANJING MEDICAL UNIVERSITY   (China)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Calcium; Excitotoxicity; LRRK2; Neurodegeneration; Parkinson's disease

Indexed keywords

LEUCINE RICH REPEAT KINASE 2; MEMANTINE; MICROTUBULE ASSOCIATED PROTEIN 2; POSTSYNAPTIC DENSITY PROTEIN 95; VESICULAR GLUTAMATE TRANSPORTER 1; AMPA RECEPTOR; GLUTAMATE RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CELL; CONTROLLED STUDY; DENDRITE; EXCITATORY POSTSYNAPTIC POTENTIAL; EXCITOTOXICITY; FEMALE; GENE MUTATION; IMMUNOFLUORESCENCE; IMMUNOREACTIVITY; IN VITRO STUDY; NERVE CELL DEGENERATION; NERVE DEGENERATION; NONHUMAN; PRIORITY JOURNAL; RAT; SYNAPSE; VOLTAGE CLAMP TECHNIQUE; BRAIN NERVE CELL; POSTSYNAPTIC POTENTIAL; PROTEIN EXPRESSION; SYNAPTIC POTENTIAL; WHOLE CELL PATCH CLAMP;

CALCIUM; EXCITOTOXICITY; LRRK2; NEURODEGENERATION; PARKINSON'S DISEASE;

ANIMALS; CALCIUM; CELLS, CULTURED; DENDRITES; DOPAMINE AGENTS; ELECTROPHYSIOLOGY; FEMALE; GLUTAMATES; IMMUNOENZYME TECHNIQUES; MEMANTINE; MUTATION; NEURONS; PROTEIN-SERINE-THREONINE KINASES; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; SYNAPSES; SYNAPTOSOMES;

EID: 84903539637     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2014.05.016     Document Type: Article

References (52)

1. Paisan-Ruiz C., Jain S., Evans E.W., Gilks W.P., Simon J., van der Brug M., Lopez de Munain A., Aparicio S., Gil A.M., Khan N., Johnson J., Martinez J.R., Nicholl D., Carrera I.M., Pena A.S., de Silva R., Lees A., Marti-Masso J.F., Perez-Tur J., Wood N.W., Singleton A.B. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 2004, 44:595-600.
2. Zimprich A., Biskup S., Leitner P., Lichtner P., Farrer M., Lincoln S., Kachergus J., Hulihan M., Uitti R.J., Calne D.B., Stoessl A.J., Pfeiffer R.F., Patenge N., Carbajal I.C., Vieregge P., Asmus F., Muller-Myhsok B., Dickson D.W., Meitinger T., Strom T.M., Wszolek Z.K., Gasser T. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 2004, 44:601-607.
3. Taymans J.M., Cookson M.R. Mechanisms in dominant parkinsonism: the toxic triangle of LRRK2, alpha-synuclein, and tau. Bioessays 2010, 32:227-235.
4. Smith W.W., Pei Z., Jiang H., Moore D.J., Liang Y., West A.B., Dawson V.L., Dawson T.M., Ross C.A. Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:18676-18681.
5. Dachsel J.C., Behrouz B., Yue M., Beevers J.E., Melrose H.L., Farrer M.J. A comparative study of Lrrk2 function in primary neuronal cultures. Parkinsonism Relat. Disord. 2010, 16:650-655.
6. Parisiadou L., Xie C., Cho H.J., Lin X., Gu X.L., Long C.X., Lobbestael E., Baekelandt V., Taymans J.M., Sun L., Cai H. Phosphorylation of ezrin/radixin/moesin proteins by LRRK2 promotes the rearrangement of actin cytoskeleton in neuronal morphogenesis. J. Neurosci. 2009, 29:13971-13980.
7. Macleod D., Dowman J., Hammond R., Leete T., Inoue K., Abeliovich A. The familial parkinsonism gene LRRK2 regulates neurite process morphology. Neuron 2006, 52:587-593.
8. Tong Y., Pisani A., Martella G., Karouani M., Yamaguchi H., Pothos E.N., Shen J. R1441C mutation in LRRK2 impairs dopaminergic neurotransmission in mice. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:14622-14627.
9. Li Y., Liu W., Oo T.F., Wang L., Tang Y., Jackson-Lewis V., Zhou C., Geghman K., Bogdanov M., Przedborski S., Beal M.F., Burke R.E., Li C. Mutant LRRK2 (R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease. Nat. Neurosci. 2009, 12:826-828.
10. Ramonet D., Daher J.P., Lin B.M., Stafa K., Kim J., Banerjee R., Westerlund M., Pletnikova O., Glauser L., Yang L., Liu Y., Swing D.A., Beal M.F., Troncoso J.C., McCaffery J.M., Jenkins N.A., Copeland N.G., Galter D., Thomas B., Lee M.K., Dawson T.M., Dawson V.L., Moore D.J. Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2. PLoS ONE 2011, 6:e18568.
11. Plowey E.D., Cherra S.J., Liu Y.J., Chu C.T. Role of autophagy in G2019S-LRRK2-associated neurite shortening in differentiated SH-SY5Y cells. J. Neurochem. 2008, 105:1048-1056.
12. Alegre-Abarrategui J., Christian H., Lufino M.M., Mutihac R., Venda L.L., Ansorge O., Wade-Martins R. LRRK2 regulates autophagic activity and localizes to specific membrane microdomains in a novel human genomic reporter cellular model. Hum. Mol. Genet. 2009, 18:4022-4034.
13. Cherra S.J., Kulich S.M., Uechi G., Balasubramani M., Mountzouris J., Day B.W., Chu C.T. Regulation of the autophagy protein LC3 by phosphorylation. J. Cell Biol. 2010, 190:533-539.
14. Wang X., Yan M.H., Fujioka H., Liu J., Wilson-Delfosse A., Chen S.G., Perry G., Casadesus G., Zhu X. LRRK2 regulates mitochondrial dynamics and function through direct interaction with DLP1. Hum. Mol. Genet. 2012, 21:1931-1944.
15. Cherra S.J., Steer E., Gusdon A.M., Kiselyov K., Chu C.T. Mutant LRRK2 elicits calcium imbalance and depletion of dendritic mitochondria in neurons. Am. J. Pathol. 2013, 182:474-484.
16. Papkovskaia T.D., Chau K.Y., Inesta-Vaquera F., Papkovsky D.B., Healy D.G., Nishio K., Staddon J., Duchen M.R., Hardy J., Schapira A.H., Cooper J.M. G2019S leucine-rich repeat kinase 2 causes uncoupling protein-mediated mitochondrial depolarization. Hum. Mol. Genet. 2012, 21:4201-4213.
17. Lichtenberg M., Mansilla A., Zecchini V.R., Fleming A., Rubinsztein D.C. The Parkinson's disease protein LRRK2 impairs proteasome substrate clearance without affecting proteasome catalytic activity. Cell death & disease 2011, 2 e196.
18. Gillardon F. Interaction of elongation factor 1-alpha with leucine-rich repeat kinase 2 impairs kinase activity and microtubule bundling in vitro. Neuroscience 2009, 163:533-539.
19. Jaleel M., Nichols R.J., Deak M., Campbell D.G., Gillardon F., Knebel A., Alessi D.R. LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity. Biochem. J. 2007, 405:307-317.
20. Ho C.C., Rideout H.J., Ribe E., Troy C.M., Dauer W.T. The Parkinson disease protein leucine-rich repeat kinase 2 transduces death signals via Fas-associated protein with death domain and caspase-8 in a cellular model of neurodegeneration. J. Neurosci. 2009, 29:1011-1016.
21. Chan D., Citro A., Cordy J.M., Shen G.C., Wolozin B. Rac1 protein rescues neurite retraction caused by G2019S leucine-rich repeat kinase 2 (LRRK2). J. Biol. Chem. 2011, 286:16140-16149.
22. Lee S., Liu H.P., Lin W.Y., Guo H., Lu B. LRRK2 kinase regulates synaptic morphology through distinct substrates at the presynaptic and postsynaptic compartments of the Drosophila neuromuscular junction. J. Neurosci. 2010, 30:16959-16969.
23. Piccoli G., Condliffe S.B., Bauer M., Giesert F., Boldt K., De Astis S., Meixner A., Sarioglu H., Vogt-Weisenhorn D.M., Wurst W., Gloeckner C.J., Matteoli M., Sala C., Ueffing M. LRRK2 controls synaptic vesicle storage and mobilization within the recycling pool. J. Neurosci. 2011, 31:2225-2237.
24. Xiong Y., Coombes C.E., Kilaru A., Li X., Gitler A.D., Bowers W.J., Dawson V.L., Dawson T.M., Moore D.J. GTPase activity plays a key role in the pathobiology of LRRK2. PLoS Genet. 2010, 6:e1000902.
25. Matta S., Van Kolen K., da Cunha R., van den Bogaart G., Mandemakers W., Miskiewicz K., De Bock P.J., Morais V.A., Vilain S., Haddad D., Delbroek L., Swerts J., Chavez-Gutierrez L., Esposito G., Daneels G., Karran E., Holt M., Gevaert K., Moechars D.W., De Strooper B., Verstreken P. LRRK2 controls an EndoA phosphorylation cycle in synaptic endocytosis. Neuron 2012, 75:1008-1021.
26. Qian A., Antonov S.M., Johnson J.W. Modulation by permeant ions of Mg(2+) inhibition of NMDA-activated whole-cell currents in rat cortical neurons. J. Physiol. 2002, 538:65-77.
27. Chu C.T., Plowey E.D., Dagda R.K., Hickey R.W., Cherra S.J., Clark R.S. Autophagy in neurite injury and neurodegeneration: in vitro and in vivo models. Methods Enzymol. 2009, 453:217-249.
28. Meijering E., Jacob M., Sarria J.C., Steiner P., Hirling H., Unser M. Design and validation of a tool for neurite tracing and analysis in fluorescence microscopy images. Cytometry A 2004, 58:167-176.
29. Kim M.J., Dunah A.W., Wang Y.T., Sheng M. Differential roles of NR2A- and NR2B-containing NMDA receptors in Ras-ERK signaling and AMPA receptor trafficking. Neuron 2005, 46:745-760.
30. Ivanov A., Pellegrino C., Rama S., Dumalska I., Salyha Y., Ben-Ari Y., Medina I. Opposing role of synaptic and extrasynaptic NMDA receptors in regulation of the extracellular signal-regulated kinases (ERK) activity in cultured rat hippocampal neurons. J. Physiol. 2006, 572:789-798.
31. Wroge C.M., Hogins J., Eisenman L., Mennerick S. Synaptic NMDA receptors mediate hypoxic excitotoxic death. J. Neurosci. 2012, 32:6732-6742.
32. Hardingham G.E., Fukunaga Y., Bading H. Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways. Nat. Neurosci. 2002, 5:405-414.
33. Hardingham G.E., Bading H. Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders. Nat. Rev. 2010, 11:682-696.
34. Xia P., Chen H.S., Zhang D., Lipton S.A. Memantine preferentially blocks extrasynaptic over synaptic NMDA receptor currents in hippocampal autapses. J. Neurosci. 2010, 30:11246-11250.
35. Cribbs J.T., Strack S. Reversible phosphorylation of Drp1 by cyclic AMP-dependent protein kinase and calcineurin regulates mitochondrial fission and cell death. EMBO Rep. 2007, 8:939-944.
36. Gomez-Suaga P., Luzon-Toro B., Churamani D., Zhang L., Bloor-Young D., Patel S., Woodman P.G., Churchill G.C., Hilfiker S. Leucine-rich repeat kinase 2 regulates autophagy through a calcium-dependent pathway involving NAADP. Hum. Mol. Genet. 2012, 21:511-525.
37. Gandhi P.N., Wang X., Zhu X., Chen S.G., Wilson-Delfosse A.L. The Roc domain of leucine-rich repeat kinase 2 is sufficient for interaction with microtubules. J. Neurosci. Res. 2008, 86:1711-1720.
38. Greggio E., Jain S., Kingsbury A., Bandopadhyay R., Lewis P., Kaganovich A., van der Brug M.P., Beilina A., Blackinton J., Thomas K.J., Ahmad R., Miller D.W., Kesavapany S., Singleton A., Lees A., Harvey R.J., Harvey K., Cookson M.R. Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol. Dis. 2006, 23:329-341.
39. West A.B., Moore D.J., Choi C., Andrabi S.A., Li X., Dikeman D., Biskup S., Zhang Z., Lim K.L., Dawson V.L., Dawson T.M. Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. Hum. Mol. Genet. 2007, 16:223-232.
40. Luzon-Toro B., Rubio de la Torre E., Delgado A., Perez-Tur J., Hilfiker S. Mechanistic insight into the dominant mode of the Parkinson's disease-associated G2019S LRRK2 mutation. Human molecular genetics 2007, 16:2031-2039.
41. Smith W.W., Pei Z., Jiang H., Dawson V.L., Dawson T.M., Ross C.A. Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat. Neurosci. 2006, 9:1231-1233.
42. West A.B., Moore D.J., Biskup S., Bugayenko A., Smith W.W., Ross C.A., Dawson V.L., Dawson T.M. Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:16842-16847.
43. Greggio E., Cookson M.R. Leucine-rich repeat kinase 2 mutations and Parkinson's disease: three questions. ASN Neuro 2009, 1.
44. Lewis P.A., Greggio E., Beilina A., Jain S., Baker A., Cookson M.R. The R1441C mutation of LRRK2 disrupts GTP hydrolysis. Biochem. Biophys. Res. Commun. 2007, 357:668-671.
45. Guo L., Gandhi P.N., Wang W., Petersen R.B., Wilson-Delfosse A.L., Chen S.G. The Parkinson's disease-associated protein, leucine-rich repeat kinase 2 (LRRK2), is an authentic GTPase that stimulates kinase activity. Exp. Cell Res. 2007, 313:3658-3670.
46. Herzig M.C., Kolly C., Persohn E., Theil D., Schweizer T., Hafner T., Stemmelen C., Troxler T.J., Schmid P., Danner S., Schnell C.R., Mueller M., Kinzel B., Grevot A., Bolognani F., Stirn M., Kuhn R.R., Kaupmann K., van der Putten P.H., Rovelli G., Shimshek D.R. LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in mice. Hum. Mol. Genet. 2011, 20:4209-4223.
47. Helton T.D., Otsuka T., Lee M.C., Mu Y., Ehlers M.D. Pruning and loss of excitatory synapses by the parkin ubiquitin ligase. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:19492-19497.
48. Gehrke S., Imai Y., Sokol N., Lu B. Pathogenic LRRK2 negatively regulates microRNA-mediated translational repression. Nature 2010, 466:637-641.
49. Lin X., Parisiadou L., Gu X.L., Wang L., Shim H., Sun L., Xie C., Long C.X., Yang W.J., Ding J., Chen Z.Z., Gallant P.E., Tao-Cheng J.H., Rudow G., Troncoso J.C., Liu Z., Li Z., Cai H. Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha-synuclein. Neuron 2009, 64:807-827.
50. Berger Z., Smith K.A., Lavoie M.J. Membrane localization of LRRK2 is associated with increased formation of the highly active LRRK2 dimer and changes in its phosphorylation. Biochemistry 2010, 49:5511-5523.
51. Shin N., Jeong H., Kwon J., Heo H.Y., Kwon J.J., Yun H.J., Kim C.H., Han B.S., Tong Y., Shen J., Hatano T., Hattori N., Kim K.S., Chang S., Seol W. LRRK2 regulates synaptic vesicle endocytosis. Exp. Cell Res. 2008, 314:2055-2065.
52. Parisiadou L., Yu J., Sgobio C., Xie C., Liu G., Sun L., Gu X.L., Lin X., Crowley N.A., Lovinger D.M., Cai H. LRRK2 regulates synaptogenesis and dopamine receptor activation through modulation of PKA activity. Nat. Neurosci. 2014, 17:367-376.